cough

News

GSK abandons cough drug added in $2bn Bellus deal

Three years after buying Bellus Health and its chronic cough candidate camlipixant for around $2 billion, GSK is abandoning the programme.

News

FDA holds back MSD’s chronic cough drug again

MSD will have to return to the drawing board to chart a course for US approval of its chronic cough treatment gefapixant.

News

GSK bolsters respiratory pipeline with Bellus Health buy

GSK has agreed to acquire Canada’s Bellus Health for around $2 billion, bolting on a late-stage drug candidate for chronic refractory cough.

News

After cough drug setback, Merck partners Hyfe's tracking app

Merck & Co has signed a deal with digital health firm Hyfe that will see its cough-detecting smartphone app offered to patients in the US.

News

Bayer's pipeline takes a hit as it drops eliapixant

Bayer has abandoned development of its investigational P2X3 receptor antagonist eliapixant, despite promising efficacy data in clinical trials, on what appears to be safety grounds.

News

FDA stifles Merck's cough drug gefapixant, asking for more d...

The FDA has issued a complete response letter (CRL) to Merck & Co's gefapixant candidate for refractory chronic cough, delaying the programme and giving Bayer an opportunity to close th

GSK abandons cough drug added in $2bn Bellus deal

FDA holds back MSD’s chronic cough drug again

GSK bolsters respiratory pipeline with Bellus Health buy

After cough drug setback, Merck partners Hyfe's tracking app

Bayer's pipeline takes a hit as it drops eliapixant

FDA stifles Merck's cough drug gefapixant, asking for more d...

Novo sues Lilly over 'misleading' GLP-1 ad campaigning

Discover a new era of healthcare panel engagement: Grounded ...

cough

Editor's Picks